Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages

Alumis Inc. (NASDAQ:ALMS) has earned an average recommendation of “Buy” from the nine research firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $26.57.

A number of analysts recently commented on the company. Oppenheimer assumed coverage on Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Alumis in a research report on Monday, March 10th.

Institutional Investors Weigh In On Alumis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Foresite Capital Management VI LLC purchased a new stake in shares of Alumis in the fourth quarter worth $33,033,000. Samsara BioCapital LLC bought a new stake in Alumis during the third quarter valued at about $34,886,000. Geode Capital Management LLC purchased a new position in shares of Alumis in the third quarter valued at about $3,266,000. Norges Bank bought a new position in shares of Alumis in the fourth quarter worth about $1,606,000. Finally, Foresite Capital Management V LLC grew its position in shares of Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after purchasing an additional 194,459 shares in the last quarter.

Alumis Trading Down 0.4 %

Shares of ALMS opened at $4.57 on Friday. The firm has a fifty day simple moving average of $6.07 and a two-hundred day simple moving average of $8.86. Alumis has a 1-year low of $4.36 and a 1-year high of $13.53.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.